Analyst Yun Zhong of Wedbush maintained a Buy rating on BioMarin Pharmaceutical, retaining the price target of $94.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Yun Zhong has given his Buy rating due to a combination of factors that support BioMarin’s ability to sustain attractive long‑term growth. The company’s 2025 revenue outlook aligns with market expectations and is paired with management’s ambition for enduring double‑digit revenue expansion into the 2030s. BioMarin is reinforcing its leadership in achondroplasia through Voxzogo, leveraging a broad label that enables early treatment, strong adherence, and an extensive global presence, while also pursuing label and indication expansions in hypochondroplasia and other skeletal disorders. Ongoing regulatory and legal strategies, including an sNDA for full approval and actions related to orphan exclusivity and competition, aim to preserve and extend this competitive edge.
In addition, recent pipeline updates provide incremental upside to the story. BMN‑351 has shown encouraging, dose‑responsive dystrophin expression in Duchenne muscular dystrophy patients, with more detailed data and higher‑dose results expected over the coming quarters. BMN‑333, a next‑generation CNP analog with weekly dosing and markedly higher CNP exposure, is advancing into a Phase 2/3 program while maintaining the target of a 2030 launch in achondroplasia. Finally, the planned acquisition of Amicus is expected to be operationally accretive shortly after closing, broadening BioMarin’s rare‑disease portfolio and unlocking underpenetrated international markets for Fabry and Pompe therapies, collectively strengthening the company’s growth and earnings profile.
According to TipRanks, Zhong is an analyst with an average return of -3.8% and a 43.56% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Rezolute, and Protagonist Therapeutics.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $120.00 price target.